AstraZeneca-Backed JV Sued By Genentech Over Avastin Biosimilar

Centus Biotherapeutics Refuses To Delay Launch Until Litigation Resolved

 
• By Dean Rudge
  
Gavel
Notice of commercial marketing was provided by Centus in April this year • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin